Genetic Biomarkers Define Subgroup of Likely Prostate Ca ImmunoTx Responders (CME/CE)

(MedPage Today) -- Still, not all microsatellite-high/mismatch repair-deficient patients benefited from pembrolizumab
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news